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Animal Experimentation and Its
Relevance to Man
by D. G. Hoel*
Theproblemofquantitatively estimating humancancerriskbased upon animal carcinogenesis studiesis
reviewed. Mathematical functions for dose-response relationships are discussed with particular emphasis
on multistage models. These models are based upon a single cell somatic mutation theory for the car-
cunogenesis process. It is shown that the multistage model and others which incorporate background
additively are well approximated in the low dose region by a linear function. The relationship between
tine-to-tumor and the multistage model is indicated. This relationship is important when dealingwith less
than life time exposure such as with data from many occupational studies. Design ofbioassay experiments
and its impact on risk estimation is noted. Finally, the problem of species-to-species extrapolation is
considered.
Introduction
The problem of identifying human carcinogens
and assessing their potency will often depend, out
of necessity, on laboratory experimentation. This
ranges from DNA chemistry to chronic exposures in
lifetime animal studies. Epidemiological studies in
carcinogenesis are naturally more appropriate for
assessing human risk. Unfortunately they require
long term prior exposures to man which do not exist
with new compounds. For older compounds labo-
ratoryandepidemiological studies hopefully interact
in a creative manner.
The problem I wish to discuss is how one can
estimate human risk to a carcinogen based upon
laboratory studies. This question involves several
problems concerning the appropriateness of animal
models forpredicting effects in man. In the standard
lifetime, rodent bioassay such as the one used by the
National Cancer Institute there are several ways in
which to arrive at incorrect conclusions. For ex-
ample, often concerns are expressed about the
statistical errors relating to sample size, etc., and
also to the possible biological errors in the sense that
the particularly chosen rodent strains may not be
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relevant to man for the type of carcinogen under
consideration.
Ifa particular animal model is a reasonable qual-
itative predictorofhuman cancer, how reasonable is
it as a quantitative predictor of carcinogenesis po-
tency in man? Clearly, if the regulation of environ-
mental carcinogens involves risk-benefit consid-
erations, we must have acceptable methods for
estimating effects in man at low exposure levels
based upon laboratory animal studies at relatively
highexposure levels. These highexperimental levels
are necessitated by limited size (cost) of the animal
study and the need for observed experimental ef-
fects. This raises interesting experimental design
considerations. On the one hand we require high
statistical powerfor confident qualitative identifica-
tion of carcinogenesis, and this is obtained at high
dose levels. On the other hand experimentation at
lowdoselevels isdesiredforpredictingeffects atlow
exposure levels.
Dose-Response Models in
Carcinogenesis
In order to estimate carcinogenic effects, some
assumptions or models are needed which relate the
frequency of tumor with exposure level of the car-
cinogen in question. If the true form of the dose-
response function were known, one could correctly
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within a stated degree ofstatistical uncertainty. This
would provide the first step in a human risk assess-
ment. The low dose estimates based upon the ex-
perimental animal data and dose-response model
must then be extrapolated to man. This requires a
considerable number of biological assumptions and
is an uncertain process at best.
Several quantitative theories of carcinogenesis
have been proposed which relate tumor incidence
with both dose rate and duration of exposure of the
carcinogen. These models generally assume that the
carcinogenesis process is single cell in origin and is
the result of several stages which can include so-
matic mutation. The transitional events are individu-
ally assumed to depend linearly on dose rate. This
then leads in general to a model in which the proba-
bility of tumor is approximately a low order poly-
nomial in dose rate. In the low dose region which
would relate to environmental levels, one finds that
the response is well approximated by a linear func-
tion of dose rate (1-4). Another class of dose-
response models which have been applied are those
which have ahistory inbioassay work. Forexample,
both the ligistic and probit functions are used for
estimating LD5o in toxicology. Mantel and Bryan (5)
have applied the probit to low dose estimation in
carcinogenesis. Its drawback is primarily that the
model is not based upon a mathematical description
ofa biologic mechanism as is the case with the mul-
tistage somatic mutation model. Since it produces
quitedifferent results in the low dose region itproba-
bly should not be applied in those cases where it is
believed that the carcinogen is direct acting with
cellularDNA asisproposed in themultistage models
(4, 6).
Of the multistage models, the one discussed by
Armitage and Doll (3) has received considerable at-
tention (4, 6-9). The function which is used states
that the probability of a tumor by time t using dose
rate d is
P(d, I = 1 - exp {-g(d)h(t)}
where
k
g(d) = [ (ai + i d)
witha>i' °,f3i' Ofori= 1, ...,k. This represents a
k-stage or mutational step model with dosage and
time factoring. The above mentioned authors have
developed maximum likelihood estimatesforthe un-
known parameters in the model. Further they have
approximate confidence estimates on the low dose
estimates of the probability of tumor. These proce-
dures are mathematically complicated in that com-
puting algorithms are required in order to obtain the
estimates. Recently Guess et al. (6) applied these
algorithms to experimental carcinogenesis data on
vinyl chloride, DDT, chloroform, DMN, and diel-
drin. In all of these cases k = 1 or 2 was found to
provide the best fit, although DMN yielded a zero
estimate of the linear coefficient. In each case the
upperbound ofrisk was estimated tobe linearat low
dose as one would theoretically anticipate.
It was previously mentioned that the multistage
models were approximately linear at low dose rates.
An important question is: how good is the linear
approximation? It may be that linearextrapolation is
aperfectly adequate method and much simpler than
using complicated computer algorithms. Further-
more, there is the intuitive beliefthat the lower con-
vex portion of a typical dose-response curve would
be bounded above by a straight line (10). It is felt,
however, that a line is a too conservative upper
bound in that it greatly overestimates the risk at low
dose levels. It has been shown by Crump et al. (4)
thatthelinearapproximation tothemultistage model
is quite good ifa background or spontaneous tumor
rate is present. For example, we defined, and dm as
the dose associated with agiven small probability of
tumor in excess ofbackground when we use a linear
model and a multistage model, respectively. Let k
denote the numberofstages in the carcinogenic pro-
cess and define p by
(1 + p)P(O) = P(de)
where de is the experimental dose and P(d) is the
probability oftumor at dosed. It was then shown by
Crump et al. (4) that approximately
dmld s pl/{k[(1 + p)llk - 1]}
Table 1. Upper bound values ofdm/d, for selected k andp.
dm/di
p= p= p= p= p=
k 0.1 0.5 1 10 100
1 1 1 1 1 1
2 1.02 1.11 1.21 2.16 5.52
5 1.04 1.18 1.35 3.25 13.18
00 1.05 1.23 1.44 4.17 21.67
Thus linear extrapolation in the lower convex por-
tion ofthe dose response curve is both a reasonable
upperbound anddirectestimate oftheprobability of
tumor (Table 1). This is an appropriate procedure to
use unless there is specific information concerning
the mechanism of the carcinogenic process which
would indicate a model other than the multistage.
This might be the case, for example, with certain
promoters or cocarcinogens.
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simplistic in nature. The multistage model assumes
that the mutational step is proportional to the ad-
ministered dose rate. This ignores the influences of
pharmacokinetics which may indicate a changing
proportion of active metabolite with administered
dose level. Also immune response and DNA repair
systems are not taken into account. Even without
these biological complications the models are fairly
complex, which indicates that we are still alongway
from a nonlinear methodology in which one would
have much biological confidence.
Time To Tumor
Most dose-response studies in animal experi-
mentation are plots of dose rate versus total tumor
incidence for the duration of the study. In large
studies there is often sufficient data to plot cumula-
tivetumorincidence versus age. Thisisthendonefor
eachdose and the curves compared. Models are also
fit to data and have the possibility ofuse in low dose
estimation. Albert and Altshuler (11) have fit the
log-normal model of Blum and Druckery to several
sets of laboratory data. Also Whittemore and
Altshuler (12) have fit both the Weibull and log-
normal model to the physician smoking data ofHill
andDoll. Aswiththeordinarydose-response models
one finds that there usually are not sufficient data to
distinguish between competing models. Yet the
choice of a time-to-tumor model can greatly change
any estimated low dose effects.
Ithasbeensuggested (13)thatthetimetofirsttmor
or latency period increases with decreasing dose.
Then with a sufficiently small dose the time to first
tumor will exceed man's lifetime, thus producing an
effective carcinogenic threshold. Unfortunately as
shown by Guess and Hoel (14), the observed time to
first tumorwill increase with decreasing doseforthe
multistage model, yet no true threshold will occur at
low doses with this model. In other words, a non-
threshold model will predictthatthe datawill lookas
though a threshold in time exists.
Using the Armitage and Doll (3) multistage model
with the incorporation oftime-to-tumor one has for
the age-specific incidence rate
k
I(t,d) = ktk-l H (ai + fid)
i = I
withk the number ofstages andd the dose rate. The
power of the duration of exposure t corresponds to
what is seen with vital statistics data on human
cancer types. Whittemore and Altshuler (12) found,
for example, with the lung cancer and cigarette
smoking data thatI(t,d) = ct5d, where t represented
the duration of smoking while d was the daily con-
sumption rate. This shows the importance of the
duration of exposure in any attempt to estimate
risks.
Design and Detection
The routine screening of compounds for car-
cinogenic activity is a slow and expensive process
using lifetime rodent studies. These assays, such as
used by NCI, are designed for detection of activity
and are not intended to provide dose response infor-
mation needed for low dose risk estimation. It is
necessary to use high dose experiments in order to
generate as much statistical poweras possible. Even
so, weak carcinogenic activity may very well go
undetected. Forexample, suppose one is comparing
50 control animals with 100 treated animals using
Fisher's exact test and nonrandomized decisions.
Thenfor a = 0.01 (one-tailed) one has less than a5%
chance ofdetecting an increased tumor incidence of
5%overthebackground rate. Thiswould essentially
gounnoticed. In actual assays both sexes and maybe
two species will be used. This will increase the
power, assuming an appropriate decision rule is
appliedwhich considers the multipletestingofmany
tissues besides the replications in sex and species.
Fears et al. (15) have looked into these issues in
depth.
Ifwe want to estimate effects at low dose levels,
the high dose bioassay often will be quite useless.
For example, if the majority of the experimental
animals are positives at the lowest experimental
dose, then little can be said about when the dose-
response function turns over. In this case a straight
line may not provide an upper bound to the curve.
Crump and Langley, in an unpublished study have
considered the simplist case ofno background and a
singleexperimental dose atd. Suppose we require an
upperbounddatoadosedawhichcorresponds tothe
probabilityofcancerPa = P(da) and is assumed tobe
small. We define the upper bound da by
P{da c da} . 1 - a
and use
da-- dPaIP
where
P{P1 : P(d,)} = 1 - a
Nowda corresponds to an acceptable dose, and thus
we can select the experimental dose d, in order to
maximize the expected value of da. Crump and
Langley showed that
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E(da)P-' = d Y g(r)-1 (-) Or(d,) {1-(d1)}N-r
r =0 r
where 0(d) is the true dose-response function, N the
experimental sample size at dose dl, and g(r) in the
upperbound P1based onr tumors. Usingthis expres-
sion, Crump and Langley found considerable effects
on E(da) by the choice ofd. For several functional
formsof0(d)itappeared as ifdiisoptimizedbyusing
approximately one-half the dose which produces a
1O%o tumorincidence. This should be auseful rule of
thumb for single dose experiments.
More recently Hoel and Jennrich (16) have ob-
tainedoptimal designs forthe multistage model using
techniques ofChebyshev systems in polynomial re-
gression. If
k
P(d) = {1 - exp - Y. 1id1}
i = o
and k + 1 design points are used they obtain the
design which minimizes Var{P(do)-P(o)} where do
is the dose of interest and P(do) the estimated inci-
dence at do. They found that their optimal design
decreased the variance by afactorof3 when applied
to Maltoni's 1975 vinyl chloride study (17). Maltoni
placed his low dose experimental points equally at
d = 0, 50, 250, and 500. The Hoel and Jennrich
design suggests 27% at d = 0, 53% atd = 83, 15% at
d = 342, and 5% at d = 500. The design question,
which is still open, is how would one combine detec-
tion with low dose estimation. The problem is to
havebothhighdoselevels forpowerofdetection and
also low dose levels for risk estimation.
Species-to-Species Extrapolation
The problem ofthe appropriateness ofthe rodent
carcinogenesis study for human risk prediction is
most difficult. One usually begins by stating that of
the25 knownhumanchemicalcarcinogens all except
for possibly arsenic and benzene are also rodent
carcinogens. There is good qualitative agreement
between laboratory results and epidemiological
studies. There are, however, few well done human
studies as compared to the hundreds ofcompounds
studied in rodent bioassays. Tomatis (18) discussed
the predictiveness of long-term rodent studies. He
points out the early identification of the carcino-
genicity of diethylstilbestrol, 4-aminobiphenyl, and
vinyl chloride through experimental animal testing.
Recently short-term in vitro testing has been com-
pared with the long-term animal studies. Tests such
as Ames' Salmonella mutagenicity assay are felt to
be presumptive of carcinogenicity. This is based
upon the proposition that many types of cancer are
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the result of somatic mutations and often are single
cell in origin. Recently an IARC working group (19)
expressed the opinion that
"When there are inadequate animal data, positive
results in validated short-term tests are an indication
thatthe compound is a potential carcinogen and should
be tested in animals for an assessment of its carcino-
genicity. Negative results in short-term tests cannot be
considered sufficient to rule out carcinogenicity."
By the Ames test (20, 21) most of the chemical
carcinogens tested sofarare mutagenic(157/175)and
most noncarcinogens are not mutagenic (95/108).
Further, there is some preliminary work suggesting
that cancer potency in animal studies is quantita-
tively predicted by the Salmonella test (22). Much
more work is needed in this area, since few com-
pounds have been compared in this manner.
Meselson has considered in a NAS report (23)
several human carcinogens (benzidine, chlor-
naphazine, DES, aflatoxin Bi, vinyl chloride, and
cigarette smoke) and compared the sensitivity of
man with laboratory animal species. He found using
the most sensitive animal species as a predictor for
man to be approximately correct for benzidine,
chlornaphazine and cigarette smoke. For the other
three compounds man was observed not to be as
sensitive as predicted from the animal studies.
Studies such as the one conducted by Meselson
will, at least empirically, answer the question as of
the precision of risk estimation. The process of
quantitativelyestimatingcarcinogeniceffects in man
will improve especially with better incorporation of
pharmacokinetic considerations and understanding
of environmental and genetic differences in human
populations. With respect to the precision of risk
estimates, however, there is not an apparent
theoretical method for quantifying biological errors.
Thus we are dependent upon empirical experience
which is somewhat inadequate at the present time.
Rall (24) has discussed species differences in car-
cinogenesis testing in some detail, paying particular
attention to pharmacological differences and
similarities in the species. He concludes that "labo-
ratory animal carcinogenicity tests predict well for
man and that such tests do offer a mechanism by
whichthe prediction ofhumancarcinogenesis is pos-
sible before human exposure and with reasonable
accuracy."
In gathering empirical evidence for the qualitative
predictability of animal studies for man, careful use
of epidemiological evidence is needed. The most
straightforward situation is when onedeals with data
from direct studies. Lung cancer and smoking is a
good example where careful modelling ofboth level
Environmental Health Perspectivesand duration of exposure has been considered (25,
12). Fromthis studyonefeelsthataccurateestimates
of risk can be made, at least for British physicians
whosmoke. Extendingthese estimates tothegeneral
population may still be quite reasonable. This as-
sumes that we are interested in the median man and
feel that the British physician is an adequate model.
Errors of magnitude do occur, however, when we
attempt to estimate the risks to susceptible sub-
groups inthe population such as uranium miners and
asbestos workers. Genetic and environmental sus-
ceptibles are oftennotidentified norpredicted. Thus
synergistic effects are a real problem and often will
be unanticipated.
Ecological or indirect studies are much more dif-
ficulttoassesswithrespecttobothpredictability and
precision. These studies attempt to correlate vital
statistics data and environmental exposure data.
Further, the studies attempt toquantitatively predict
health effects based upon exposure datausually em-
ploying simple regression models. Examples include
mortality rates and various air pollutants. Also
chloroform levels in drinking water and bladder,
colon, and rectal cancer rates have been studied
recently. It is known that the predicted health effect
oftenwillvarydepending uponthe statistical method
ofanalysis used. The reliability and thus usefulness
ofthisquantitative approach toriskestimationis still
not understood.
Estimates are needed for risks to the general
population from various environmental agents when
the only human data available is from high exposure
groups. For example, risk calculations have been
made for populations living in the vicinity of vinyl
chloride plants. These estimates are extrapolations
from highly exposed worker populations.
Even with the application of dose response and
exposure duration models, childhood and in utero
exposures are not included in the model. Thus seri-
ous biological errors could be made. It is thejudge-
ment ofthe possibility ofsuch model errors which is
needed for the quantification ofthe precision ofthe
risk estimates. The statistical aspects can be prop-
erly assessed. What is needed is quantification con-
cerning the likelihood of the model being represen-
tative of the true state of nature.
Finally, one technical point should be discussed.
Inthecomparisonofhumandatawithanimaldatawe
are often dealing with less than lifetime human ex-
posures. Much of the human data is obtained from
industrial exposures. Applying the multistage model
one finds a critical dependency on the duration of
exposure. As discussed earlier the age specific rate
often is ofthe formdtk-l where the numberofstages
k is 4, 5, or 6. Now, for a human study with 20 years
exposure and followup one would underestimate the
lifetime riskby afactorofabout500 [(70/20)]k-1 with
k = 6, and it is not taken into account. Thus we see
the care with which the human data must be treated
when quantitative comparisons to animal studies are
made.
Conclusion
The research area oflow dose risk estimation has
and will continue to be of statistical interest. Dose-
response modelling will also continue although we
mustbe onguard notto lose sightoftheassumptions
made. There seems always to be the danger of pro-
viding more mathematical sophistication than the
biological knowledge warrants.
Statistical errors or confidence statements do not
include a quantification of biological errors (e.g.,
wrong mathematical or biological model). Since the
biological errors cannot be easily if at all quantified
they tend to be ignored. The possible biological er-
rorscouldeasilyoverwhelm the statistical errors and
thusconsiderable care is needed inthe interpretation
ofconfidence statements.
Specific research needs from a statistical stand-
point include the following: (1) additional bioassay
design ofexperiments research, including improved
methods of statistical testing as well as risk estima-
tion; (2) incorporation of pharmacokinetic consid-
erations including repair systems in dose-response
estimation; (3) empirical studies which attempt to
quantitate the effects in man withthose in laboratory
animal experiments; (4) attention to quantifying the
effects ofsusceptible subgroups and also synergistic
activity.
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